Traws Pharma (NASDAQ:TRAW) Issues Quarterly Earnings Results, Beats Expectations By $0.39 EPS

Posted by Geri Gentry on May 17th, 2026

Traws Pharma (NASDAQ:TRAW – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.39, FiscalAI reports.

Traws Pharma Stock Up 15.3%

Shares of TRAW stock opened at $1.88 on Friday. The business has a 50-day moving average price of $1.68 and a two-hundred day moving average price of $1.86. Traws Pharma has a 12-month low of $0.99 and a 12-month high of $3.27. The firm has a market cap of $19.10 million, a P/E ratio of -1.11 and a beta of 1.47.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TRAW. LADENBURG THALM/SH SH raised Traws Pharma to a “strong-buy” rating in a research note on Friday, January 30th. Weiss Ratings lowered Traws Pharma from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $8.00.

View Our Latest Stock Analysis on Traws Pharma

Insider Transactions at Traws Pharma

In other news, major shareholder Orbimed Advisors Llc purchased 597,729 shares of the company’s stock in a transaction on Thursday, April 16th. The stock was purchased at an average price of $1.67 per share, with a total value of $998,207.43. Following the completion of the purchase, the insider directly owned 1,203,250 shares in the company, valued at approximately $2,009,427.50. This trade represents a 98.71% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 14.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of TRAW. Two Sigma Investments LP lifted its stake in shares of Traws Pharma by 37.1% in the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after acquiring an additional 5,955 shares during the last quarter. State Street Corp bought a new stake in shares of Traws Pharma in the 4th quarter valued at about $29,000. XTX Topco Ltd lifted its stake in shares of Traws Pharma by 294.2% in the 4th quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after acquiring an additional 31,502 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Traws Pharma by 41.9% in the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after acquiring an additional 18,213 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Traws Pharma in the 4th quarter valued at about $175,000. Hedge funds and other institutional investors own 7.95% of the company’s stock.

About Traws Pharma

(Get Free Report)

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.